Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis

Table 3 HRs and 95%CIs for the association between hepatocellular carcinoma development and different variables

Variables	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age, yr	1.06	1.01-1.11	0.0162	1.07	1.02-1.12	0.0042
Male sex	5.22	1.27-21.44	0.0222	3.67	0.69-19.56	0.128
Diabetes mellitus	3.01	0.96-9.44	0.058
Cirrhosis	8.02	2.35-27.29	< 0.0012	4.38	1.06-18.14	0.0412
APRI > 0.54	3.43	0.43-27.19	0.243
APRI-r1 > 0.54	5.10	1.64-15.86	0.0052	3.94	1.04-14.94	0.0432
Creatinine, μmol/L	1.02	0.99-1.05	0.222
Albumin, g/L	0.85	0.75-0.96	0.0072
Bilirubin, µmol/L	1.01	0.98-1.03	0.514
ALP, U/L	0.997	0.994-1.00	0.104
ALT, U/L	0.996	0.987-1.00	0.331
AST, U/L	0.996	0.975-1.01	0.467
GGT, U/L	1.00	0.999-1.001	0.975
PT, s	1.40	0.99-1.98	0.0602
AMA positivity	0.52	0.16-1.75	0.292
Globulin, mg/dL	0.99	0.90-1.08	0.804
IgM, mg/dL	1.00	0.997-1.002	0.830
Suboptimal treatment response, Rotterdam criteria1	5.95	1.59-22.26	0.0082	2.18	0.45-10.58	0.334

¹In the multivariate analyses, albumin was not included as this variable was already included in the Rotterdam criteria.

²P values < 0.05. ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AMA: Anti-mitochondrial antibody; APRI: AST to platelet ratio index; APRI-r1: APRI at 1 year after treatment; AST: Aspartate aminotransferase; CI: Confidence interval; GGT: Gamma-glutamyl transferase; HR: Hazard ratio; IgM: Immunoglobulin M; PT: Prothrombin time.